AT7519, a CDK2 inhibitor (70.0% cytotoxicity), has shown excellent preclinical anti-tumor responses against MYCN-amplified neuroblastoma (64), and is currently in phase II clinical trials for adults (NCT00390117) and children (NCT01627054). This evidence concerns the gene MYCN and neoplasm.